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Although the liver is not generally regarded as a target organ for estrogens, several 
clinical observations and a number of physiological studies suggest that it is. The 
identification of estrogen receptors in liver cytosol and nuclei support this conclusion. 1, 2 
We shall discuss several of the more important physiological and clinical effects of 
estrogens upon the liver (table 1) and shall illustrate them by brief case reports. 
Case Presentation 
WILLIAM E~FLING, M.D. 
S. C., a 20-year-old, nulliparous white female was 
given Librium (chlordiazepoxide) and Enovid (mes-
tranol 0.16 mg, norethynodrel 10 mg) because of anxiety 
and irregular menses in 1963. Five days later pruritus 
began and persisted; 3 weeks later jaundice appeared. 
Medications were discontinued, but pruritus and jaun-
dice, associated with an elevated serum alkaline phos-
phatase level, led to an exploratory laparotomy. The 
liver, gallbladder, and bile ducts appeared normal ex-
cept for a solitary 2.5-cm stone in the gallbladder. A 
cholecystectomy was done. Liver biopsy showed centri-
lobular bile stasis only. She was well until June 1964 
when she was given Enovid again and within 5 days 
developed pruritus and jaundice. Apercutaneous needle 
liver biopsy showed cholestasis. Liver function tests 
were compatible with cholestasis. The drug was stopped 
and she recovered promptly. 
There was no past medical history or family history 
of jaundice or pruritus during pregnancy. 
Effects of Estrogens on the Liver 
FRANCIS R. SIMMON, M.D. 
The effects of estrogenic components of oral contracep-
tives on the liver have received increasing attention 
Address requests for reprints to: Fred Kern, Jr., M.D., Professor 
of Medicine, Head, Division of Gastroenterology, University of 
Colorado Medical Center, 4200 E. 9th Avenue, B158, Denver, Colo-
rado 80262. 
In June 1965 she was first seen at Colorado General 
Hospital. Her serum glutamic oxalacetic and glutamic 
pyruvic transaminases, bromsulfophthalein (BSP) re-
tention, and other liver tests were normal. An intrave-
nous cholangiogram was also normal. She was chal-
lenged with the estrogen, mestranol, 0.16 mg per day, 
and on the 5th day developed an elevated serum biliru-
bin and alkaline phosphatase level and increased BSP 
retention 45 min after a standard dose. 3 Maximum 
transport of BSP was reduced and storage capacity was 
increased. Liver biopsy showed only canalicular bile 
plugs. Challenge with the progestational agent, nore-
thynodrel, 10 mg per day for 14 days, produced fatigue 
only. 
In 1968, she became pregnant and remained well 
until pruritus gravidarum developed during the latter 
part of the third trimester. 
because of their association with abnormal liver func-
tion, formation of cholesterol gallstones, and their pos-
sible relationship to hepatic cancer. My presentation 
will emphasize three points about oral contraceptives. 
(1) They cause a predictable and reversible reduction in 
hepatic excretory function, primarily owing to the estro-
genic component. (2) Jaundice occurs primarily in those 
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TABLE 1. Principal effects of estrogens upon the liver 
Physiological effects 
Decreased bile flow 
Diminished secretion of organic anions 
Diminished bile acid synthesis and secretion 
Clinical syndromes 
Pruritus gravidarum, intrahepatic cholestasis of pregnancy 
Cholesterol gallstones 
Hepatic adenomas, benign nodular hyperplasia" 
" There is controversy about the nature of the relationship be-
tween adenomata and hyperplasia and estrogen. See text. 
patients with inheritable or acquired reduction in he-
patic excretory function. (3) In animals, the effect of 
estrogens on hepatic excretory process provides insight 
into the normal physiology and biochemistry of bile 
formation. 
Oral contraceptives are a combination of synthetic 
estrogens and progestogens, with the latter compound 
always present in much higher concentrations. Studies 
in animals have shown that specific structural features 
in the steroid nucleus and side chain are required to 
cause abnormalities in liver functions. 4 Decreased clear-
ance of BSP is primarily related to the presence of a 
phenolic A ring, whereas potency is accentuated by the 
addition of 17 a-alkyl substitution. Both of these prop-
erties are present in synthetic estrogens, ethinyl estra-
diol, and mestranol, which are used in oral contracep-
tives. Progestogens, on the other hand, are derivatives 
of either 19-nortestosterone or progesterone. Synthetic 
progestogens derived from 19-nortestosterone also con-
tain a 17 a-alkyl substitution. Decreased hepatic excre-
tory capacity and abnormal liver function tests have 
been reported only with these progestogens. These ef-
fects may result from metabolism of 19-nortestosterone 
progestogens to estrogens, rather than a direct effect of 
the progestogen itself. 
The difference in potency between mestranol (estro-
gen) and norethynodrel (progestogen) is clearly shown 
in the patient presented here. Abnormal liver function 
tests were produced by administration of the oral con-
traceptive containing both mestranol and norethynodrel 
and by the estrogenic component alone, but not the 
progestogen alone. These observations emphasize that 
the major cause of abnormalities associated with oral 
contraceptives is apparently related to the estrogenic 
component of the pill, although progestogens may play 
an additional role.:; 
In most asymptomatic individuals taking oral contra-
ceptives the serum bilirubin, transaminase, and alka-
line phosphatase activities are normal or only minor 
transient elevations are observed. The significance of 
these alterations is uncertain for their frequency in a 
controlled population is unknown. However, the 
changes appear to be more marked and constant in 
postmenopausal women. I; 
In contrast to these variable effects on liver function 
tests a predictable reduction in BSP excretion is ob-
served when hepatic storage and the maximum biliary 
excretion (Tm) are determined. Clearance of BSP from 
the blood involves uptake of the dye and hepatic stor-
age, intracellular conjugation with gluthathione, and 
subsequent excretion into bile by a rate-limiting trans-
port process. In hepatic disease both storage and BSP 
Tm are reduced. However, in patients receiving oral 
contraceptives only BSP Tm is reduced approximately 
50%, whereas storage capacity is either unaltered or 
slightly increased. 7 This effect of oral contraceptives is 
mimicked by the administration of large doses of the 
natural estrogen, estradiol. Thus, the estrogenic com-
ponent of oral contraceptives predictively and also re-
versibly reduces hepatic excretory function. 
Why does pruritus or jaundice develop in some sub-
jects and not in others? Current evidence suggests that 
the majority of individuals who develop jaundice from 
oral contraceptives have reduced biliary excretory ca-
pacity before drug ingestion. 8 The normal liver has a 
large excretory capacity reserve, and a reduction of 50% 
generally is not associated with jaundice. This is illus-
trated in figure 1 where the maximum capacity of rats 
to excrete bilirubin is compared to serum bilirubin 
levels. 9 Many steroids are capable of reducing bilirubin 
transport capacity, but serum bilirubin levels do not 
become abnormally increased until excretory capacity 
is reduced below 10% of control. Thus, if similar hepatic 
excretory reserve exists in man, preexisting abnormali-
ties in biliary excretion must exist before jaundice will 
appear after oral contraceptive use. 
Approximately 50% of patients developing jaundice 
with the use of oral contraceptives have intrahepatic 
cholestasis of pregnancy, a disorder which was first 
described in detail in 1954. Although it has a worldwide 
distribution, it is most common in Chile and the Scan-
dinavian countries. Because no specific tests are avail-
able, intrahepatic cholestasis of pregnancy is diagnosed 
by its clinical features. It usually appears in women in 
the second half of the pregnancy, and is characterized 
by severe pruritus, mild jaundice, and "cholestatic" 
liver function tests. All these abnormalities rapidly 
disappear in the first days postpartum. The term pruri-
tus gravidarum is applied to pregnant women complain-
ing of persistent itching, and who also have "choles-
tatic" liver function abnormalities but without jaundice. 
Pruritus gravidarum and intrahepatic cholestasis of 
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FIG. 1. Relationship between hyperbilirubinemia and bilirubin 
excretory maximum ("Tm") in Wistar rats treated with various 
steroids and icterogenin. 9 
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pregnancy may alternate in different pregnancies in the 
same women, and thus both are considered different 
clinical forms of the same disease. Neither functional 
nor histological sequelae have been described for either 
clinical syndrome. Although genetic factors are consid-
ered important in its pathogenesis, the cause of intra-
hepatic cholestasis of pregnancy is unknown. Challenge 
studies with hormones, as in our patient discussed here, 
suggest that patients are abnormally "sensitive" to 
estrogens. Rather than causing an increased response, 
cholestasis may result from further reduction of an 
already decreased hepatic excretory capacity for organic 
anions. Oral contraceptives increase serum bilirubin, 
but not bile acids, in the Dubin-Johnson syndrome, a 
selective disorder in bilirubin excretion.8 In addition, 
hyperbilirubinemia is increased by oral contraceptives 
in patients with cirrhosis. Although a constitutional 
defect in BSP transport is likely to be present in 
intrahepatic cholestasis of pregnancy, it has not been 
specifically identified. However, the effects observed in 
Dubin-Johnson syndrome and cirrhosis support the hy-
pothesis that oral contraceptive-induced cholestasis in 
most cases depends upon an underlying abnormality in 
hepatic excretion of organic anions. 
The effect of ethinyl estradiol on the hepatic transport 
of bile acids has been examined in detail, for this is the 
major organic anion excreted into bile. Studies in man 
and rats are consistent with a diffuse effect of estrogen 
on the bile canalicular membrane and/or the presumed 
carrier molecules for organic anions. A number of 
investigators have shown that administration of ethinyl 
estradiol to rats does not alter basal bile acid excretion, 
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FIG. 2. Effect of ethinyl estradiol administration (5 mg per kg per 
day x 5 days) on bile flow, basal bile acid excretion, and maximum 
capacity to excrete organic anions. 
Cholesterol Gallstones 
FRED KERN, JR., M.D. 
Cholesterol cholelithiasis is more common among 
women than men in every population that has been 
studied (fig. 4). This difference between men and women 
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FIG. 3. Schematic model of hepatic transport of bile acids. 
but decreases hepatic transport of biliary water, and 
the maximum capacity to excrete organic anions, such 
as bile acids, bilirubin, and BSP (fig. 2). 
Bile acids are transported across both sinusoidal and 
canalicular membranes by a carrier-mediated process 
shown schematically in figure 3. Optimal membrane 
transport is dependent upon both the numbr of putative 
bile acid carriers, and the fluidity of the membrane lipid 
bilayer which apparently permits the carrier to undergo 
movement. In spite of a reduction in bile acid transport 
to 65% of control, the number of putative carriers was 
unchanged by ethinyl estradiol treatment. 10 Abnormal 
transport after ethinyl estradiol treatment is associated 
with decreased membrane lipid mobility, probably the 
result of an increased content of cholesterol in liver 
surface membrane fractions. 11 This change in mem-
brane lipid physical structure found in animal studies 
suggests similar changes in canalicular membranes 
may occur with oral contraceptive use in humans and 
thus account for decreased hepatic transport of organic 
anions. 
In conclusion, oral contraceptives cause a dose-re-
lated, predictable, and reversible abnormality in he-
patic excretory function in humans and experimental 
animals. The estrogenic component, which contains 
both a phenolic A ring and a 17 a-alkyl substitution, is 
apparently the major cause of liver functional abnor-
malities, particularly in patients with either genetic or 
acquired forms of reduced biliary secretory capacity. 
Finally, animal studies suggest that estrogens may 
cause abnormal hepatic transport of organic anions by 
alteration of membrane lipids, rather than by decreas-
ing the number of putative carrier proteins. 
begins during puberty (fig. 5) and is present throughout 
the childbearing years, focusing attention upon the 
effects of female sex hormones. The administration of 
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FIG. 4. Incidence of gallstones in four different population groups. 
Note the increase in females during the child bearing years. The 
data from Malmo and Prague l ' and the United States"J are based 
upon autopsy studies. The Pima Indian study was based upon 
clinical and cholecystographic data. 14 
ell 
W 
ell 
« 
u 
20 
10 
5 
• 
10 
AGf(Yeors) 
15 
FIG. 5. Cholelithiasis in children in a Swedish community hospi-
tal, reproduced from Acta Chirurgica Scandinauica 15 with permis-
sion. Note the increase in number of female cases at the time of 
puberty. 
oral contraceptive steroids to premenopausal women 
doubles the incidence of cholesterol cholelithiasis. The 
administration of estrogens to postmenopausal women 
(fig. 6) and to men has similar effects.17, 18 Parity is 
possibly directly correlated with the incidence of gall-
stones. Among women who have had intrahepatic cho-
lestasis of pregnancy, gallstones develop in later life 
twice as frequently as among matched controls.19 The 
pathogenesis of stone formation in these various groups 
has not been fully explained, but all of these observa-
tions emphasize the importance offemale sex hormones. 
Cholesterol gallstones are 60 to 90% cholesterol. The 
initial step in their formation is the production of an 
abnormal bile; that is, bile containing excess choles-
terol. The normal relative molar percentage of the 
major organic components of bile- bile acids, lecithin, 
and cholesterol-is 70-85:10-25:5-10, respectively. Cho-
lesterol is held in solution in the bile in mixed micelles 
of bile acids and phospholipids. The molar proportion of 
bile acids plus lecithin to cholesterol is 15-20:1. When 
the ratio falls to 10:1 or less, excess cholesterol is present 
in supersaturated solution and, when bile in the gall-
bladder is "seeded" by precipitated pigment or other 
solid matter, cholesterol crystals precipitate out of so-
lution and initiate gallstone formation. Such bile is 
known as lithogenic. 
The possible mechanisms leading to the production of 
lithogenic bile are shown in table 2 and will be briefly 
discussed. They may be disorders of hepatic or gallblad-
der function or both. 
Excess hepatic cholesterol secretion clearly occurs in 
obesity20 and is proportional to excess weight in the 
morbidly obese.21 In less obese patients the relationship 
between biliary cholesterol secretion and percentage of 
body fat has not been carefully examined in a large 
number of patients. Evidence indicates that the major 
abnormality associated with estrogen administration is 
decreased bile acid synthesis and secretion. Lecithin 
synthesis and secretion is secondary to bile acid secre-
tion. When bile acid secretion is reduced, lecithin secre-
tion is reduced. 22, 23 (A primary defect in hepatic lecithin 
metabolism has not been described.) Cholesterol secre-
tion is less dependent upon bile acid secretion as shown 
diagramatically in figure 7. Thus, decreased bile acid 
secretion leads to lithogenic bile because relatively 
more cholesterol is secreted. 
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FIG. 6. Frequency of oral contraceptive (A) and estrogen (B) use 
among patients with surgically proven gallbladder disease and 
among matched controls. The women who used these agents had 
gallbladder (GB) disease 2 to 2.5 times more frequently than the 
controls who did not use them. Modified from studies by the Boston 
Collaborative Drug Surveillance Program. 16. 17 
TABLE 2. Possible mechanisms of production of bile containing 
excess cholesterol 
Hepatic 
Excess cholesterol secretion 
Decreased bile acid synthesis and secretion 
Decreased lecithin secretion 
Gallbladder 
Selective absorption of bile acids and/or lecithin 
Defective emptying 
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lithogenic 
Bile 
Undersaturated 
Bile 
Cholesterol Secretion 
Bile Acid Secretion 
FIG. 7. Schematic representation of the relationships between 
bile acid secretion and the secretion oflecithin and cholesterol in the 
bile. At low rates of bile acid secretion the bile is lithogenic because 
there is relatively more cholesterol than bile acid or lecithin. 
Studies of the effects of estrogens upon biliary lipids 
show the following. (1) In women taking contraceptive 
steroids, the bile becomes lithogenic24 (fig. 8). (2) In a 
single study of 3 women with a T-tube in the common 
bile duct, the administration of Premarin and Provera 
caused a decrease in cholic acid synthesis and pool size 
and an increase in the molar percentage of biliary 
cholesterol in the bile.25 (3) In rats2&-28 and hamsters29 
given ethinyl estradiol, bile acid synthesis and secretion 
decrease and biliary cholesterol secretion does not 
change (fig. 9). The bile, therefore, contains relatively 
more cholesterol. (4) In hamsters, ethinyl estradiol 
decreases the activity of cholesterol 7 a-hydroxylase, 
the enzyme that is rate limiting for the conversion of 
cholesterol to bile acids.29 (5) In the rat, ethinyl estradiol 
affects the lipid composition and physical characteristics 
of the hepatic microsomal membrane, which is the site 
of the critical steps in conversion of cholesterol to bile 
acids. 27,30 The principal change in lipid membrane 
composition is an increase in concentration of both free 
cholesterol and esterified cholesterol. Cholesterol es-
ters, which do not serve as substrate for bile acid 
synthesis, are synthesized in the hepatic microsomal 
membranes, regulated by cholesterol acyl CoA transfer-
ase, the cholesterol esterification enzyme. Increased 
activity of this enzyme seems to be a primary effect of 
estrogens, both in vitro and in vivo.30, 31 Decreased 
activity of cholesterol 7 a-hydroxylase, a microsomal 
membrane-bound lipid phase enzyme, could be second-
ary to changes in membrane lipid composition. Bonorris 
et al., 29 however, failed to find an increase in cholesterol 
of the hepatic microsomal fraction in their hamsters 
treated with ethinyl estradiol, even though, as noted, 
cholesterol 7 a-hydroxylase activity was decreased. 
The possibility of altered gallbladder function in 
response to estrogens has been incompletely studied. 
There is selective absorption of bile acids from the 
diseased gallbladder mucosa, but not from a normal 
gallbladder mucosa.32, 33 A diseased gallbladder mucosa, 
therefore, may perpetuate the conditions leading to 
stone formation, but absorptive defects probably do not 
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FIG. 9. Effect of ethinyl estradiol (5 mg per kg per day x 5) on bile 
acid synthesis and biliary cholesterol secretion in the biliary fistula, 
bile acid-depleted rat. Bile acid synthesis is approximately half that 
of the control, but cholesterol secretion is unaffected, resulting in 
bile that is more saturated with cholesterol. C, control; EE, ethinyl 
estradiol-treated. 
playa role in initiating the process. Effects of estrogens 
upon gallbladder storage capacity and contractility 
have not been well characterized. A defective response 
to stimulation has been described during various phases 
of the menstrual cycle34 and recent studies have shown 
poor contractility of the gallbladder during pregnancy. 35 
If estrogens or progestogens did produce poor contractil-
ity of the gallbladder, there could be prolonged storage 
of the bile acid pool in the gallbladder and diminished 
enterohepatic cycling of bile acids. This might decrease 
the biliary secretion of bile acids and lecithin, and 
because cholesterol secretion would not be decreased 
proportionately, the bile would become more saturated 
with cholesterol. Much remains to be learned about the 
effects offemale sex hormones on the metabolism of bile 
acids and cholesterol and about biliary physiology. 
-. 
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Case Presentation 
ROBERT DAHL, M.D. 
A 26-year-old white woman presented with 4 hr of 
nausea, vomiting, and right upper quadrant pain which 
was severe and radiated to the shoulders. Three months 
earlier similar pain occurred and resolved sponta-
neously. There was no history of jaundice, fever, chills, 
or any type of liver disease. She had used a sequential 
birth control pill 3 years before a recent pregnancy and 
shortly thereafter. Initial examination disclosed normal 
vital signs, right upper quadrant tenderness, and hy-
poactive bowel sounds. The liver and spleen could not 
be felt. A few hours after admission the patient sud-
denly became hypotensive and, after transfusions were 
started, a liver scan and celiac angiogram were per-
formed; they suggested the presence of a mass in the 
right lobe of the liver. After stabilization she was 
transferred to Colorado General Hospital for surgery. A 
12.5-cm hepatic adenoma in the right lobe of the liver 
had ruptured and bled intraabdominally. A trisegmen-
tectomy was performed. The patient did well postoper-
atively and remains well 7 years later. 
Hepatic Tumors and Oral Contraceptives 
ANDREW MALLORY, M.D. 
Since 1970, evidence has been growing that oral 
contraceptives may cause a variety ofliver tumors. This 
evidence includes: (1) a large number of case reports of 
both benign and malignant tumors in women taking 
oral contraceptives; (2) reports of regression of tumors 
after cessation of oral contraceptive therapy;36.37 (3) 
recurrence of tumors after surgical resection in patients 
continuing to take oral contraceptives.38 In addition, 
Edmondson et al. have recently reported increased 
duration of oral contraceptive use among patients with 
hepatic tumors when compared with matched controls. 39 
Although most of this evidence is circumstantial and 
has been disputed40 and the results of animal experi-
ments are conflicting,41 the evidence on balance 
strongly suggests a causal association between these 
drugs and hepatic tumors. 
Klatskin has recently reviewed the clinical details of 
117 cases described in the literature.41 The data that 
follow come largely from that review. 
The types of hepatic tumors reported are listed in 
table 3. Ten reported tumors have been malignant. The 
smaller number of cases makes it more difficult to 
establish a causal relationship with oral contraceptives. 
These tumors, therefore, will not be discussed further. 
The majority of tumors have been benign and classi-
fied as either hepatic cell adenomas (solitary, grossly 
smooth, and sharply circumscribed masses of normal-
appearing hepatocytes) or focal nodular hyperplasia 
(firm, grossly nodular masses which on cross-section 
contain a central fibrous core with radiating septa that 
divide the tumor into nodules). Although this classifi-
cation is generally accepted, many authors agree that 
some benign tumors may be difficult to classify. 
The majority of women with benign tumors had taken 
contraceptives for more than 5 years. Ten per cent, 
however, had done so far less than 12 months and, in 7 
per cent, the tumor was discovered 6 months to 10 years 
after cessation of contraceptive therapy. Presenting 
complaints are listed in table 4. 
Physical findings consist of a right upper quadrant 
mass in those with large tumors and signs of shock or 
right upper quadrant tenderness in those who have bled 
into the tumor. 
Laboratory results are usually normal. In Klatskin's 
review, serum bilirubin, alkaline phosphatase, and 
glutamic oxalacetic transaminase were mildly abnor-
mal in 5, 30, and 30%, respectively; a-fetoprotein was 
normal in all 11 patients tested. 
TABLE 3. Types of hepatic tumors in women using 
oral contraceptives" 
Tumors No. reported 
Benign 
Hepatic cell adenoma 
Focal nodular hyperplasia 
Malignant 
Hepatocellular carcinoma 
Hepatoblastoma 
Mixed hepatocellular-ductular 
79 
28 
8 
1 
1 
TABLE 4. Presenting complaints in women with benign 
hepatic tumors41 
Symptom 
Acute abdominal pain and 
shock 
Palpable mass 
Chronic or intermittent pain 
Asymptomatic 
Hepatic cell Focal nodular 
adenoma hyperplasia 
53 (68)a 
18 (23) 
1 (1) 
7 (9) 
6 (21) 
4 (14) 
4 (14) 
14 (50) 
Total 
59 (55) 
22 (21) 
5 (5) 
21 (20) 
a Numbers in parentheses are percentage of total in group. 
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Radiological findings are frequently abnormal but 
not specific. Technetium liver scans showed filling de-
fects in 81 % of patients tested. Arteriograms were 
abnormal in 90%.41 
The natural history of these tumors has not been 
adequately studied because most patients undergo sur-
gical resection. Of 12 tumors left in situ, four have 
shown regression in size in patients discontinuing con-
traceptive therapy. In none of these tumors has there 
been evidence of progression or malignant transforma-
tion. 
Surgical Treatment of Hepatic Adenoma and Focal Nodular Hyperplasia 
THOMAS STARZL, M.D. 
There is very little to add to what you have just 
heard, which was an excellent review. I would like to 
tell you about the case material that we have accumu-
lated at the University of Colorado. Seven patients have 
had hepatic resection for adenomas. The first of these 
cases was misdiagnosed. Although Dr. Dahl was kind 
enough not to point it out, the patient whose course was 
presented actually was signed out as having a hepa-
toma. She was placed on 5-flurouracil therapy for about 
3 postoperatively years. The same applied to the second 
and third cases. These errors were not picked up until 
the report by Baum et a1. 42 The surgical specimens 
eventually were reexamined by Dr. Hugh Edmondson 
of Los Angeles and by Dr. Fennell of our own pathology 
department, leading to reclassification. 
I would like to focus on the critical question which 
was raised about the association of the adenomas with 
birth control pills. Of the 7 patients at the University of 
Colorado who came to op ration, 3 did not have an 
PRE -OPERATI VE 
obvious association between the pill and their tumors. 
One was a 14-year-old girl. She had been exposed to the 
pill onlyfor about 1 week, less than 1 year previously. 
The 2nd patient was a 17-year-old woman who had 
never been on the pill. The 3rd patient was a male. 
Those of you in the audience who are skeptical of the 
pill hypothesis will be interested in an article by Guz-
man et al. 40 which contains a persuasive argument 
against the pill association . 
In considering the appropriate treatment of hepatic 
adenoma, it is important to appreciate that upwards of 
70% of these typically young ladies present with acute 
intraabdominal hemorrhage. The results may be dev-
astating. Berg, an oncologist at the University oflowa, 
surveyed that state's public health records for a number 
of years and found 4 cases of hepatic adenoma, all in 
woman who bled to death .4 :! This kind of study has 
influenced us to recommend operation for these pa-
tients, particularly because the lesions have been very 
FIG. 10. Preoperative radiographic studies . Left, 99m technetium li ver scan (anteroposterior projection) showing a very large filling 
defed. Right, selective common hepatic arteriogram. Broad arrows indicate the extent of the tumor as outlined by the abnormal 
configuration of vessels. Thin arrow points to the dorsolateral branch of the left hepatic artery. This vessel , supplying the lateral segment 
of the left lobe, was the only hepatic arterial branch preserved . (By permission of American Journal of Surgery 129:587-590, 1975. ) 
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large in our cases and ruptured in three instances. 
Dr. Mallory has covered the work-up of patients with 
suspected adenomas. Angiography is very helpful, not 
only for diagnosis but also in planning the operation 
TrlSegmentectomy 
I 
Right lobectomy 
I 
Falciform 
lig 
, 
, 
I 
Lateral segmentectomy 
I 
Left lobectomy 
FIG. 11. Common hepatic resections of which there are only four. 
The most radical procedure, trisegmentectomy, involves removal of 
the true right lobe plus the medial segment of the left lobe. The 
least radical procedure, lateral segmentectomy, was incorrectly 
termed left lobectomy in the older literature. 
(fig. 10). Obviously the ultimate diagnosis in these cases 
is usually made either by needle biopsy or preferably at 
laparotomy. 
To return now to treatment. One possibility is with-
drawal of the estrogenic treatment, but obviously this 
could not be done if there were no estrogen treatment, 
as in almost half of our own cases. 
I believe that resection should be carried out in a very 
formal way in which one or more anatomical segments 
are removed, as opposed to piecemeal removal of the 
tumors as has been recommended by some authorities. 
Figure 11 shows the anatomical units that I believe can 
be safely resected. 41 Formal right lobectomy or formal 
left lobectomy consists of two segments. There is the 
possibility of performing a so-called extended right 
hepatic resection (trisegmentectomy) which involves 
removal of three full segments or about 80 to 85% of the 
liver mass. This has been necessary in the treatment of 
3 of our 7 patients, including the patient presented, 
leaving only the small left lateral segment. The fourth 
possibility is removal of the left lateral segment, which 
used to be known as the left lobe because it is the liver 
tissue to the left of the falciform ligament. 
The 7 patients in the Colorado series were treated 
with extended right hepatic resection in three in-
stances, standard right hepatic lobectomy in 3 more 
cases, and a left hepatic lobectomy in the other case. 
These seven resections for adenoma were part of a 
FIG. 12. Specimen from a 17-year-old girl with a huge hepatic adenoma. Hepatic resection (85%) was required. The case is the same as in 
figure 10. 
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total experience of 37 hepatic resections which I have 
performed or at which I assisted at the University of 
Colorado. There were no deaths in this group of 37. All 
7 of the patients with adenoma are alive and well with 
follow-ups of 1 to 8 years. Obviously the operation is 
quite a safe one even when large quantities of liver 
must be removed (fig. 12). Therefore, surgical treatment 
can be applied somewhat more freely than if there were 
a high operative risk. 
That concludes my remarks about hepatic adenoma. 
To complete the picture, I would like to mention sepa-
Discussion 
Dr. Ernest Borek: We have observed recently that 
after the administration of three different carcinogens 
there is an effect which is germane to the subject of this 
conference. Ethionine, thioacetamide, and actinomycin 
D raise the progesterone level by as much as 10-fold 
above normal in the immature chick. 45 It is noteworthy 
that none of these carcinogens is positive in the Ames 
test. None of them is mutagenic. Whether there is any 
relationship between the production of this hormonal 
imbalance and carcinogenesis is under investigation. 
Dr. Francis Simon: Both synthetic progestogens and 
estrogens in high doses have been shown in male and 
female rats to cause an increase over expected frequency 
of liver cell tumors. 46 
Dr. Ernest Borek: Carcinogenesis is highly species 
specific. Chronic administration of progesterone pro-
duces mammary tumors in the beagle. Moreover, ad-
ministration of progesterone enhances tumor formation 
by dimethylbenzanthracene in the beagle. 
Dr. Charles Scoggin: Do males receiving stilbesterol 
for prostatic carcinoma develop cholestasis? 
Dr. Francis Simon: Minor transient abnormalities in 
liver function tests were noted in a small series of 
patients treated with estrogens for prostatic cancer. 
Similar to oral contraceptive use in women, the most 
consistent abnormality seen, in approximately 50% of 
the patients, was increased retention of BSPY 
Dr. Richard Bynny: What is the relationship between 
estrogen administration and the multiple venous lakes 
or dilated sinusoids in the liver? 
Dr. Andrew Mallory: There is evidence that oral 
contraceptives or estrogens may affect the vasculature 
of benign tumors as well as the vasculature of normal 
liver tissue. In benign tumors, sinusoidal congestion, 
subintimal fibrosis and medical hypertrophy of me-
dium-sized arterioles, and peliosis hepatis-like lesions 
have been described. In normal livers, several investi-
gators have reported sinusoidal congestion41 and at 
angiography, pooling of contrast material suggesting 
peliosis hepatis. 41,48 
Dr. Fred Kern: Peliosis hepatis has been described in 
at least 2 or 3 patients receiving estrogens as well as in 
those receiving anabolic steroids. 
Dr. Sunder Mehta: Is a percutaneous liver biopsy 
rately our surgical experience with focal nodular hyper-
plasia. We have seen only 2 patients with this diagnosis 
whom we have submitted to resection. One had a lateral 
segment removed and the other had an 85% resection. 
However, my general recommendation for patients with 
focal nodular hyperplasia is not to operate because those 
patients do not frequently bleed as Mallory's citations 
of Klatskin's review41 has demonstrated. Because it 
tends to be a quiescent lesion, I put focal nodular 
hyperplasia into a quite different category than the 
benign hepatic adenoma. 
indicated or contraindicated when liver tumors associ-
ated with the "pill" are suspected. 
Dr. Thomas Starzl: I would rather not have liver 
tumors biopsied in advance of resection. These patients 
should be operated upon once and by someone who can 
carry out a hepatic resection if that is indicated. Unfor-
tunately, the usual situation in our series is that the 
patients have had needle biopsies or, more commonly, 
open biopsies. This creates a log of technical problems 
and is inconsistent with good oncological therapy if the 
liver mass proves to be a malignant tumor. 
Dr. Karl Sussman: Do alterations in hepatic function 
and bile acid metabolism occur during the menstrual 
cycle? 
Dr. Francis Simon: Except for BSP retention I do not 
know any evidence of alterations in liver function tests 
during the menstrual cycle. In some individuals reten-
tion of BSP at 45 min is apparently increased in the 
luteal and menstrual phases of the cycle. 49 However, 
BSP Tm, a more sensitive study, has not been examined 
during the cycle. 
Dr. Fred Kern: Dr. Sussman's question is probably 
important, but there are few answers. There have been 
two studies of biliary lipid composition with conflicting 
findings. Biliary lipid composition was studied at three 
phases during the ovulatory cycle: at the time of men-
struation, at the time of ovulation, and during the 
luteal phase. In the first study, biliary lipids were the 
same in all three phases. 50 In the second study the bile 
became lithogenic in the luteal phase. 51 Dr. Erfling and 
I are looking at this question in considerable detail at 
the present time. 
Dr. Antonie de Torrente: Cirrhosis is associated with 
an increased incidence of gallstones. Is this because of 
alterations of bile acid metabolism? 
Dr. Francis Simon: You are correct, but the increase 
is attributable to bilirubin stones, not to cholesterol 
gallstones. 52 It has been suggested that the pigment 
stones may result from increased hemolysis or another 
mechanism, rather than from alterations in bile acid 
metabolism. 
Dr. Fred Kern: I would like to ask Dr. Mallory a 
question with regard to the controversy about whether 
benign hepatic adenomata are pill-related. It is, of 
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course, always extremely difficult to determine cause 
and effect in events that occur rarely, but I wonder if 
we get any useful information from the sex ratio of non-
pill related cases? 
Dr. Andrew Mallory: In the non-pill cases of benign 
hepatic tumors, Klatskin found that, of 138 cases re-
ported, 124 or 90% were in women, most of whom were 
between the ages of 19 and 50. This propensity for tumor 
development in women of the childbearing age is fur-
ther evidence supporting a hormonal relationship. 
Dr. Thomas Starzl: I wish to add a detail about the 
Guzman study from Minnesota to which I referred 
earlier. The authors studied all of the case material 
from 1940 onward, and compared the prepill era with 
the pill era. There was no statistically significant differ-
ence in the incidence during these two times, but the 
tumors were bigger in more recent times. Consequently, 
Guzman et al., were willing to concede that the pill was 
an accelerator of growth. They were challenging the 
concept that it was an initiator of growth. 
Dr. Andrew Mallory: They and others have also 
made the interesting observation that not only are the 
tumors larger in association with the pill, but also they 
seem to bleed much more frequently. 
Dr. Robert Schrier: Dr. Starzl, could you comment on 
any derangements or complications which are associ-
ated with 85% hepatic resection, such as alterations in 
the renin angiotensin-aldosterone system, predisposi-
tion to lactic acidosis, or any other long term complica-
tions? 
Dr. Thomas Starzl: As you know, we were interested 
in the possibility of aldosterone changes which we 
investigated with you 2 or 3 years ago. There seemed to 
be hyperaldosteronism for a period. However, in the 
long run no matter how extensive the resection, the 
patients became completely well. One of our patients, 
whose specimen is shown in figure 12 had a resection 
that approached 90% and probably is one of the most 
extreme subtotal resections that has ever been success-
fully done. 5:! That patient developed ascites that lasted 
for several months. She lost all of her hair and her 
fingernails. These findings completely went away after 
ESTROGEN RECEPTORS 
6 or 7 months even though liver regeneration, as judged 
by scan, was not complete. Since then, I have heard of 
another similar pateint in whom the syndrome of re-
versible ascites and alopecia developed. But, in the long 
run, if the patients survive operation, they can expect 
to become completely normal even though the mass of 
hepatic tissue is not completely restored. 
Dr. Sunder Mehta: Is the angiogram diagnostic in 
differentiating hyperplasia from adenoma? 
Dr. Thomas Starzl: No, there are no specific angio-
graphic features that permit a differential diagnosis. 
Dr. Fred Kern: In summary, today we have presented 
2 patients who probably represent examples of compli-
cations of oral contraceptives, and have discussed 
briefly the current state of knowledge about three major 
clinical effects of estrogens upon the liver: cholestasis, 
cholesterol gallstones, and hepatic adenomas. The cer-
tainty of the latter association has been questioned. 
Some of the major effects of estrogens upon the hepatic 
cell are shown diagramatically in figure 13. 
REFERENCES 
1. Mester J, Baulier E: Nuclear estrogen receptor of chick liver. 
Biochim Biophys Acta 261:236-244, 1972 
2. Eisenfeld AJ, Weinberger M, Aten R, et al: E8trogen receptor in 
the mammalian liver. Science 191:862-865, 1976 
3. Urban E, Frank BW, Kern F Jr: Liver dysfunction with mes-
tranol but not with norethynodrel in a patient with enovid® 
induced jaundice. Ann Intern Med 68:598-602,1968 
4. Gallagher TF, Mueller NW, Kappas A: Estrogen pharmacology. 
IV. Studies on structural basis for estrogen-induced impairment 
of liver function. Medicine (Baltimore) 45:471-479,1966 
5. Beck P, Venable RL, Hoff DL: Mutual modification of glucose-
stimulated serum insulin responses in female Rhesus monkeys 
by ethinyl estradiol and nortestosterone derivatives. J. Cl En-
docrinol 41:44-53, 1975 
6. Stoll BA, Andrews JT, Motterum R: Liver damage from oral 
contraceptives. Br Med J 1:960-961, 1966 
7. Kleiner GJ, Kresch L, Arias 1M: Studie8 of hepatic excretory 
function. II. The effect of morethynodrel and mestranol on 
bromosulfalein sodium metabolism in women of childbearing 
age. N Engl J Med 273:420-423, 1965 
8. Cohen L, Lewis C, Arias 1M: Pregnancy, oral contraceptives and 
chronic familial jaundice wi th predominantly conjugated hyper-
CANALICULAR MEMBRANE 
~ Increased Cholesterol Ester Content Decreased Fluidity 
Decreased (Na+K+)ATI'ose 
Decreased Bile Flow 
Decreased Bile Acid Tm 
Increased ehol. Acyl CoA HYPERPLASIA 
Transferase Activity 
Increased Cholesterol Ester Content 
Decreased Cholesterol 7a Hydroxylase Activity 
Decreased Bile Acid Synthesis 
FIG. 13. Diagram of major effects of estrogens upon the liver cell, 8howing sites of action and proposed mechanism8 of effects on the 
canalicular and microsomal membranes. 
522 CLINICAL CONFERENCE Vol. 75, No.3 
bilirubenemia (Dubin-Johnson Syndrome). Gastroenterology 
62:1182-1190, 1972 
9. Arias 1M: Studies on a plant acid (icterogenin) and certain 
anabolic steroids on the hepatic metabolism of bilirubin and 
sulfobromphathalein (BSP). Ann NY Acad Sci 104:1014-1025, 
1963 
10. Simon FR, Sutherland E, Accatino L: The effect of cholestasis 
produced by ethinyl estradiol (EE) on bile acid binding and 
(Na+K~)ATPase activity in rat liver surface membranes (LSM) 
(abstr). Clin Res 24:105, 1976. 
11. Simon FR, Sinensky M, Kern F, et al: Reversal of ethinyl 
estradiol (EE) induced cholestasis: correlative changes in liver 
surface membrane (LSM) structure and function (abstr). Clin 
Res 25:318, 1977 
12. Zahor A, Sternby NH, Kagan A, et al: Frequency of choleli-
thiasis in Prague and Malmo-an autopsy study. Scand J 
Gastroenterol 9:3-7,1974 
13. Newman HF, Northup JD: Collective review: the autopsy inci-
dence of gallstones. lnt Abst Surg 109:1-13, 1959 
14. Sampliner RE, Bennet PH, Comess LJ, et al: Gallbladder 
disease in Pima Indians: demonstration of high prevalence and 
early onset by cholecystography. N Engl J Med 283:1358-1364, 
1970 
15. Nilsson S: Gallbladder disease and sex hormones: a statistical 
study. Acta Chir Scand 132:275-279, 1966 
16. Report from Boston Collaborative Drug Surveillance Pro-
gramme: Oral contraceptives and venous thromboembolic dis-
ease, surgically confirmed gallbladder disease, and breast tu-
mours. Lancet 1:1399-1404, 1973 
17. Report from Boston Collaborative Drug Surveillance Program: 
Surgically confirmed ballbladder disease, venous thromboem-
bolism, and breast tumors in relation to post-menopausal estro-
gen therapy. N Engl J Med 290:15-18, 1974 
18. The Coronary Drug Project Research Group: Gallbladder disease 
as a side effect of drugs influencing lipid metabolism: experience 
in the Coronary Drug Project. N Engl J Med 296:1185-1190,1977 
19. Furhoff A, Hellstrom K: Jaundice in pregnancy. Acta Med 
Scand 196:181-189. 1974 
20. Bennion LJ, Grundy SM: Effects of obesity and caloric intake on 
biliary lipid metabolism in man. J Clin Invest 56:996-1011, 1975 
21. Freeman JB, Meyer PD, Printen KJ, et al: Analysis of gallblad-
der bile in morbid obesity. Am J Surg 129:163-166, 1975 
22. Nilsson S, Schersten T: Importance of bile acids for phospholipid 
secretion into human hepatic bile. Gastroenterology 57:525-532, 
1969 
23. Northfield TC, Hofmann AF: Biliary lipid output during 3 meals 
and an overnight fast. 1. Relationship to bile acid pool size and 
cholesterol saturation of bile in gallstone and control subjects. 
Gut 16:1,1975 
24. Bennion W, Ginsberg RL, Garnick MB, et al: Effects of oral 
contraceptives on the gallbladder bile of normal women. N Engl 
,J Med 294:189-192, 1976 
25. Pertsemlidis D, Panveliwalla D, Ahrens EH: Effects of clofibrate 
and of an estrogen-progestin combination on fasting biliary 
lipids and cholic acid kinetics in man. Gastroenterology 66:565-
573, 1974 
26. Davis RA, Kern F Jr: Effects of ethinyl estradiol and phenobar-
bital on bile acid synthesis and biliary bile acid and cholesterol 
excretion. Gastroenterology 70:1130-1135, 1976 
27. Davis RA, Kern F Jr: Reversal by Triton WR-1339 of the effects 
of ethinyl estradiol (EE) on cholesterol and bile acid (BA) 
metabolism in the rat (abstr). Gastroenterology 72:1045, 1977 
28. Kern F, Eriksson H, Curstedt T, et al: Effect of ethynylestradiol 
on biliary excretion of bile acids, phosphatidylcholines, and 
cholesterol in the bile fistula rat. J Lipid Res 18:623-634, 1977 
29. Bonnorris GG, Coyne MJ, Chung A, et al: Mechanism of 
estrogen-induced saturated bile in the hamster. J Lab Clin Med 
90:963-970, 1977 
30. Davis RA, Showalter R, Kern F Jr: Triton WR-1339 reversal of 
ethinyl estradiol induced hepatic cholesterol esterification. Bio-
chern J (in press), 1978 
31. Schweppe JS, Jungmann RA: The effect of hormones on hepatic 
cholesterol ester synthesis in vitro. Proc Soc Exp BioI Med 
131:868-870, 1969 
32. Ostrow JD: Absorption by the gallbladder of bile salts, sulfo-
bromophthalein, and iodipamide. J Lab Clin Med 74:482-494, 
1969 
33. Ostrow JD: Absorption of organic compounds by the injured 
gallbladder. J Lab Clin Med 78:255-264, 1971 
34. Nilsson S, Stattin S: Gallbladder emptying during the normal 
menstrual cycle. A cholecystographic study. Acta Chir Scand 
133:648-652, 1967 
35. Erfling W, McKinley C, Coan P, et al: Pregnancy in humans 
affects gallbladder (GB) function and the lithogenic index (Ll) of 
bile. Gastroenterology (in press), 1978 
36. Edmondson HA, Reynolds TB, Henderson B, et al: Regression of 
liver cell adenomas associated with oral contraceptives. Ann 
Intern Med 86:180-182, 1977 
37. Stauffer JQ, Lapinski MW, Honold DJ, et al: Focal nodular 
hyperplasia of the liver and intrahepatic hemorrhage in young 
women on oral contraceptives. Ann Intern Med 83:301-306, 1975 
38. Kay S, Shatski PF: Ultrastructure of a benign liver cell ade-
noma. Cancer 28:755-762, 1971 
39. Edmondson HA, Henderson B, Benton B: Liver-cell adenomas 
associated with the use of oral contraceptives. N Engl ,J Med 
294:470-472, 1976 
40. Guzman IJ, Gold JH, Rosai J, et al: Benign hepatocellular 
tumors. Surgery 82:495-503, 1977 
41. Klatskin G: Hepatic tumors: possible relationship to use of oral 
contraceptive. Gastroenterology 73:386-394, 1977 
42. Baum JK, Holts F, Booksteon JJ, et al: Possible association 
between benign adenomas and oral contraceptives. Lancet 2:926, 
1973 
43. Berg JW, Ketalaar RJ, Rose EF, et al: Letter: hepatomas and 
oral contraceptives. Lancet 2:349-350,1974 
44. Starzl TE, Bell RH, Beart RW, et al: Hepatic trisegmentectomy 
or extended right lobectomy: relation to other liver resections. 
Surg Gynecol Obstet 1:429, 1975 
45. Sharma OK, Borek E: The carcinogen ethionine elevates proges-
terone levels. Nature 265:748, 1977 
46. Lingeman C: Liver-cell neoplasms and oral contraceptives. Lan-
cet 1:64, 1974 
47. Winkler K, Poulsen H: Liver disease with periportal sinusoidal 
dilatation: a possible complication to contraceptive steroids. 
Scand J GastroenteroI1O:699-704, 1975 
48. Pliskin M: Peliosis hepatis. Radiology 1:29-30, 1975 
49. Allan JS, Tyler ET: Biochemical findings in long-term oral 
contraceptive usage. 1. Liver function studies. Fertil Steril 
18:112-123, 1967 
50. Bennion LJ, Ginsberg RL, Garnick MB, et al: Effects of the 
normal menstrual cycle on human gallbladder bile. N Engl J 
Med 294:1187, 1976 
51. Low-beer TS, Wicks ACB, Heaton KW, et al: Variation in bile 
composition and serum lipids during the menstrual cycle. In 
Bile acid metabolism in health and disease. Edited by G Paum-
gartner, A Steihl. MTP Press, Lancaster, England, 1977, p 183-
190 
52. Nichols R, Rinaudo PA, Conn HO: Increased incidence of chole-
lithiasis in Laennec's cirrhosis. A postmortem evaluation of 
pathogenesis. Gastroenterology 63:112-121,1972 
53. Starzl TE, Putnam CW, Groth CG, et al: Alopecia, ascites and 
incomplete regeneration after an 85-90% liver resection. Am J 
Surg 129:587-590, 1975 
